Pfizer Eyes First-To-Market Opportunity In Alopecia

 
• By Jessica Merrill

Inflammation and Immunology Chief Scientific Officer Michael Vincent talked to Scrip about the first positive Phase II data testing a JAK inhibitor for hair loss caused by alopecia areata, next steps for development and the broader I&I portfolio.

Front view of a balding woman before and after hair treatment. Divided image of the head. Two halves. Sticker revealing healthy scalp. Female alopecia. Isolated vector illustration.

More from Immunological

More from Therapy Areas